Compare Kroger Co (KR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs BIO-TECHNE Corp — how do they compare? Kroger Co trades at $61.45 (market cap $36.27B), while BIO-TECHNE Corp trades at $72.5 (market cap $11.36B). The key difference: Kroger Co is far larger — about 3.2× BIO-TECHNE Corp's market cap, and Kroger Co pays the higher dividend (2.54%). Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and BIO-TECHNE Corp for 64 Days on average.
| KR | TECH | |
|---|---|---|
Market Cap | $36.27B | $11.36B |
Volume | 8,301,523 | 5,390,331 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $72.61 |
52-Week Low | $55.53 | $43.31 |
Typical Hold Time | 108 Days | 64 Days |
Enterprise Value | $57.69B | $11.39B |
Dividend Yield | 2.54% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.04, up 3.02% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $147.12B revenue, 14.24% ROE, and consistent dividend payments. Recent earnings beat expectations in two of the last three quarters, while the company demonstrates strong cash flow generation with $5.79B from operations in 2025. Technical indicators show the stock trading near pivot point resistance at $62 with bullish moving average alignment.
Kroger presents a compelling value opportunity with low P/S ratio of 0.26 and 47.7% analyst buy ratings, though near-term risks include integration challenges from the Giant Eagle acquisition and cost pressures. The consensus price target of $70.62 suggests 15.7% upside potential, supported by digital growth initiatives and retail media expansion, but investors should monitor identical sales trends and margin pressures in the competitive grocery sector.
Bio-Techne (TECH) trades at $72.45, down 0.11% on the day, near its 52-week high of $72.70. The stock shows bullish technical signals with strong moving average support. Fundamentally, the company maintains solid gross margins of 65.77% but faces declining net income margins, dropping from 24.6% in 2022 to 6.01% in 2025. Recent shareholder approval of Merck KGaA's acquisition at $73 per share provides a clear near-term catalyst.
The pending acquisition offers limited upside from current levels but provides downside protection. However, declining profitability trends and elevated valuation ratios (P/E 62.46) pose risks if the deal falls through. Investors should weigh the acquisition premium against fundamental deterioration in earnings quality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
